Navigation Links
ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
Date:2/13/2008

ietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com.

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian se
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...nt bank KTA Capital,s client Neuren Pharmaceutical...le note private placement with a U.S. institutiona...KTA Capital as Neuren,s exclusive placement agent ...PRWEB) November 23, 2009 -- The independent New Yo...ital") has announced that its client Neuren P...
(Date:11/24/2009)...irstCall/ -- Sigma-Aldrich Corporation (Nasdaq: S...nce on Tuesday, December 1st at 1:45 PM GMT in Lon... via live audio broadcast over the Internet availa...com/ . Users can click the "Webcast" icon to acc...gma-Aldrich is a leading Life Science and High Tec...
(Date:11/24/2009)...ewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NG...oping and commercializing novel pain management th...sident and Chief Executive Officer, is scheduled t...Care Conference, to be held December 1-2, 2009 at ...,, Mr. DiTonno and Stephen Ghiglieri, Chief Fin...
(Date:11/24/2009)... been met for patients with advanced-stage, or ...Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on endoc...e efficacy data from a Phase 2 study with its targ...ly AN-152), in patients with advanced or recurrent...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...American Association for Cancer Research ...il 15 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX )...from its,registrational bioequivalence clinical st...American Association for Cancer Research (AACR),An...harmacokinetic,equivalence observed between an emu...
...Trust, Inc.,(NYSE: BMR ) today announced that Mar...ncurrently with the company,s annual meeting of st..., the Ernest W. Hahn Professor of Real Estate Fina...enter for Real Estate at the,University of San Die...rectors since its initial public offering in 2004,...
...ting Late-Breaking Clinical Trials ...IEGO, April 14 ,Medivation, Inc. (Nasdaq: MDVN ) ...2 clinical trial showed that the Company,s novel a... reduce serum levels of prostate specific,antigen ...anded dose group,tested after three months of trea...
Other Biology Technology:ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 2ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 4ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 5BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors 2BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 3
(Date:11/26/2009)...vember 26, 2009) Whitehead researchers have devel...to pinpoint specific genes and proteins used by pa... In most human cell cultures genes are present in... from the mother. Gene inactivation by mutation is...activated, the second copy usually remains active ...
(Date:11/25/2009)...roduced in the stomach, may be used to boost resis...disease, Yale School of Medicine researchers repor...ournal of Neuroscience . , Parkinson,s disease i...an area of the midbrain known as the substantia ni... Reduced production of dopamine in late-stage Par...
(Date:11/25/2009)...R 25, 2009 Soil is the linchpin of the environmen...et. Despite that, many students see soil as "just ...oil science educators are challenged with the task...critical importance of soil in the environment. ,...th science teachers at University of Nebraska-Linc...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Hormone ghrelin can boost resistance to Parkinson's disease 2It's not just dirt! 2New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 1New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 2New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 3New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 4New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 5New Shape HF 26amp 3B 238482 3B Cardiopulmonary Testing System to be on Display at 2009 American Association of Heart Failure Nurses Annual Meeting 48399 1New Shape HF 26amp 3B 238482 3B Cardiopulmonary Testing System to be on Display at 2009 American Association of Heart Failure Nurses Annual Meeting 48399 2New Shape HF 26amp 3B 238482 3B Cardiopulmonary Testing System to be on Display at 2009 American Association of Heart Failure Nurses Annual Meeting 48399 3Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Car 4580 1
... be exhausting. When fruit flies mate, the females...s when an immune reaction starts. This is shown in...ng in the scientific publication, Journal of Evol...avioral studies and genomic technology, so-called ... show how fruit fly females are affected by mating...
...ase is available in French . , Montreal, Febru... life has been resolved. According to a study publ...ntral scientists have proposed a new theory for ho...aged to self-assemble as a critical step in the ge... is a complex structure it features a clear hierar...
...Observatory of Singapore (EOS) which aspires to be... addressing several of civilisation,s most serious...namis, volcanic eruptions and climate change aims...ocus on Southeast Asia, that could potentially sav...highly anticipated first Research Centre of Excell...
Other Biology News:Life secret exposed: Scientists unlock mystery of molecular machine 2The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 2The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 3
...ip arrays have been developed for affinity capture... ProteinChip chemical surfaces allow differential ...hemical properties. Each chip has eight different ...d the chips are color-coded with a unique hydropho...
Thermal Printer, 120 V from Bio-Rad
...Assay with FAM-Labeled Substrate (green fluorescen...e serine protease activation • No lysing, fix...its utilize cell-permeable, fluorescently labeled ... chymotrypsin-like activity in whole living cells....
...ay systems, known as ChemiArrayTM Mouse Cytokine A...ith current methodologies. Besides the ability to ...nt a more accurate reflection of active cytokine l... and no amplification step is needed. Furthermore,...
Biology Products: